Small molecules blocking PD-1/PD-L1 pathway may have shorter half-life, increased tissue penetration, oral bioavailability, increased anti-tumor activity and lower toxicity compared to monoclonal antibodies [80]. The gene discussed is CD274; the disease is neoplasm.